183 related articles for article (PubMed ID: 35002232)
1. Enhanced Oral Bioavailability of Epalrestat SBE
Alvi Z; Akhtar M; Mahmood A; Ur-Rahman N; Nazir I; Sadaquat H; Ijaz M; Syed SK; Waqas MK; Wang Y
Int J Nanomedicine; 2021; 16():8353-8373. PubMed ID: 35002232
[TBL] [Abstract][Full Text] [Related]
2. Utilization of Gelling Polymer to Formulate Nanoparticles Loaded with Epalrestat-Cyclodextrin Inclusion Complex: Formulation, Characterization, In-Silico Modelling and In-Vivo Toxicity Evaluation.
Alvi Z; Akhtar M; Rahman NU; Hosny KM; Sindi AM; Khan BA; Nazir I; Sadaquat H
Polymers (Basel); 2021 Dec; 13(24):. PubMed ID: 34960901
[TBL] [Abstract][Full Text] [Related]
3. The preparation, characterization, and pharmacokinetic studies of chitosan nanoparticles loaded with paclitaxel/dimethyl-β-cyclodextrin inclusion complexes.
Ye YJ; Wang Y; Lou KY; Chen YZ; Chen R; Gao F
Int J Nanomedicine; 2015; 10():4309-19. PubMed ID: 26170666
[TBL] [Abstract][Full Text] [Related]
4. Enhanced dissolution and skin permeation profiles of epalrestat with β-cyclodextrin derivatives using a cogrinding method.
Furuishi T; Takahashi S; Ogawa N; Gunji M; Nagase H; Suzuki T; Endo T; Ueda H; Yonemochi E; Tomono K
Eur J Pharm Sci; 2017 Aug; 106():79-86. PubMed ID: 28546106
[TBL] [Abstract][Full Text] [Related]
5. Polymer-free electrospun nanofibers from sulfobutyl ether
Yildiz ZI; Celebioglu A; Uyar T
Int J Pharm; 2017 Oct; 531(2):550-558. PubMed ID: 28445768
[TBL] [Abstract][Full Text] [Related]
6. In silico Analysis of Sulpiride, Synthesis, Characterization and In vitro Studies of its Nanoparticle for the Treatment of Schizophrenia.
Kecel-Gunduz S; Budama-Kilinc Y; Cakir-Koc R; Zorlu T; Bicak B; Kokcu Y; Kaya Z; Ozel AE; Akyuz S
Curr Comput Aided Drug Des; 2020; 16(2):104-121. PubMed ID: 31244443
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of naringenin-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles for ocular drug delivery.
Zhang P; Liu X; Hu W; Bai Y; Zhang L
Carbohydr Polym; 2016 Sep; 149():224-30. PubMed ID: 27261746
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of Valsartan Oral Bioavailability by Preparing a Microwave-Irradiated Inclusion Complex with Sulfobutyl Ether β-Cyclodextrin Using a Central Composite Face Design for Optimising Process Parameters.
Maddula VR; Dachuru RSR
AAPS PharmSciTech; 2023 May; 24(5):115. PubMed ID: 37160765
[TBL] [Abstract][Full Text] [Related]
9. Preparation and Evaluation of N-Trimethyl Chitosan Nanoparticles of Flurbiprofen for Ocular Delivery.
Shinde UA; Joshi PN; Jain DD; Singh K
Curr Eye Res; 2019 May; 44(5):575-582. PubMed ID: 30632402
[TBL] [Abstract][Full Text] [Related]
10. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable and biocompatible polymeric nanoparticles for enhanced solubility and safe oral delivery of docetaxel: In vivo toxicity evaluation.
Sadaquat H; Akhtar M; Nazir M; Ahmad R; Alvi Z; Akhtar N
Int J Pharm; 2021 Apr; 598():120363. PubMed ID: 33556487
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study.
Sharma M; Sharma R; Jain DK; Saraf A
Int J Biol Macromol; 2019 Aug; 135():246-260. PubMed ID: 31128197
[TBL] [Abstract][Full Text] [Related]
13. Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study.
Radwan SE; Sokar MS; Abdelmonsif DA; El-Kamel AH
Int J Pharm; 2017 Jun; 526(1-2):366-379. PubMed ID: 28487189
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, biological activities and molecular docking of Epilobium parviflorum aqueous extract loaded chitosan nanoparticles.
Egil AC; Ozdemir B; Gok B; Kecel-Gunduz S; Budama-Kilinc Y
Int J Biol Macromol; 2020 Oct; 161():947-957. PubMed ID: 32544580
[TBL] [Abstract][Full Text] [Related]
15. Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate:
Aljaeid BM; El-Say KM; Hosny KM
Drug Dev Ind Pharm; 2019 Jul; 45(7):1130-1139. PubMed ID: 30884977
[No Abstract] [Full Text] [Related]
16. Cliv-92-Loaded Glycyrrhetinic Acid-Modified Chitosan Nanoparticles for Enhanced Hepatoprotection-Preparation, Characterization, and In Vivo Evaluation.
Yadav KS; Srivastava N; Rai VK; Ranjana ; Tandon S; Mina PR; Chanda D; Kalleti N; Rath SK; Darokar MP; Ajayakumar PV; Shanker K; Yadav NP
AAPS PharmSciTech; 2021 Oct; 22(8):259. PubMed ID: 34704177
[TBL] [Abstract][Full Text] [Related]
17. Development and biological evaluation of protective effect of kidney targeted N-acetylated chitosan nanoparticles containing thymoquinone for the treatment of DNA damage in cyclophosphamide-induced haemorrhagic cystitis.
Prajapati C; Agrawal YO; Agnihotri VV; Mahajan UB; Patil KR; Patil DD; Patil CR
Int J Biol Macromol; 2022 Aug; 214():391-401. PubMed ID: 35714868
[TBL] [Abstract][Full Text] [Related]
18. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
19. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
20. Design and Optimization of New Enteric Nanoparticles of Ceftriaxone for Oral Delivery: In vitro and in vivo Assessments.
Maghrabia A; Boughdady M; Meshali M
Int J Nanomedicine; 2021; 16():5937-5953. PubMed ID: 34511899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
